Since FRDA is caused by a deficiency in frataxin, which is controlled at transcriptional, post-transcriptional, and post-translational levels, several strategies are being developed to restore frataxin levels toward normal in order to treat the disease, including gene therapy, gene editing, and interventions to slow down the turnover of frataxin protein. The gene discussed is FXN; the disease is Friedreich ataxia.